High risk factors and clinical efficacy of pulmonary fungal infection in patients with acute exacerbation of chronic obstructive pulmonary disease

Abstract

Abstract:

Objective To further explore the high-risk factors of secondary fungal infection in patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)and to analyze whether differences of clinical efficacy and expenses exist among the group of clinically diagnosed and suspected. Method This study to collect the clinical data of AECOPD from January 2014 to August 2017 in the Department of respiration in our hospital, and to analysis the sex, age, course of disease, basic disease, antibiotics, corticosteroids, hospitalization time, costs and clinical efficacy. Result This study included 633 AECOPD patients in total, 90 cases with pulmonary fungal infection. The risk factors of secondary pulmonary fungal infection in COPD patients were age (≥ 70 years), course (≥ 10 years), basic diseases (≥ 2 kinds), the use of combination antibiotics and systemic hormone (P<0.05). Of 90 pulmonary fungal infection patients, 4 cases were correctly diagnosed (excluded), 41 cases were clinically diagnosed and 45 cases were suspected. No differences were observed on gender, age, course, basic diseases, the use of antibiotics and hormone, and clinical effects in the latter two groups, but the group of suspected was better than the group of clinically diagnosed on hospitalization time (P=0.016) and costs (P=0.019). Conclusion High risk factors for fungal infection should be assessed as early as possible for patients with AECOPD who were not adequately treated with conventional anti-infection therapy. Early antifungal therapy for suspected patients can reduce hospitalization time and costs.

Key words: AECOPD, fungal infection, high-risk factor, clinical efficacy

CLC Number:

R519

WANG Qun, ZHANG Qiang, HUANG Jing, HAN Shu-hua, ZHU Xiao-li. High risk factors and clinical efficacy of pulmonary fungal infection in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Chinese Journal of Mycology, 2018, 13(1): 15-19.

References

[1] Serrano R, Gimeno A, Plumed L, et al. Epidemiological profile and sensitivity pattern of isolates causing invasive fungal infection vs. colonizing isolates in non-neutropenic critically ill patients[J]. Rev Iberoam Micol,2013, 30(1):14-20.
[2] Tadec L, Talarmin JP, Gastinne T, et al. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of candidemia at a single French hospital:a 7-year study[J]. Mycoses,2016,59(5):296-303.
[3] Chinet T, Dumoulin J, Honore I, et al. The place of inhaled corticosteroids in COPD[J]. Rev Mal Respir. 2016, 33(10):877-891.
[4] Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations:a European Respiratory Society/American Thoracic Society guideline[J]. Eur Respir J,2017,49(3):1600791.
[5] 肺真菌病诊断和治疗专家共识[J]. 中华结核和呼吸杂志,2007,30(11):821-834.
[6] 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第四次修订版)[J]. 中华内科杂志,2013,52(8):704-709.
[7] Claus FV, Gerard JC, Fernando JM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report:GOLD executive summary[J]. Eur Respir J,2017, 49(6):1750214.
[8] Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease:current burden and future projections[J]. Eur Respir J, 2006,27(2):397-412.
[9] Perera PN, Armstrong EP, Sherrill DL, et al. Acute exacerbations of COPD in the United States:inpatient burden and predictors of costs and mortality[J]. COPD, 2012, 9(2):131-141.
[10] Wu X, Chen D, Gu X, et al. Prevalence and risk of viral infection in patients with acute exacerbation of chronic obstructive pulmonary disease:a meta-analysis[J]. Mol Biol Rep,2014, 41(7):4743-4751.
[11] Boixeda R, Rabella N, Sauca G, et al. Microbiological study of patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) and the usefulness of analytical and clinical parameters in its identification (VIRAE study)[J]. Int J Chron Obstruct Pulmon Dis,2012,7:327-335.
[12] Alsalman J, Zaid T, Makhlooq M, et al. A retrospective study of the epidemiology and clinical manifestation of invasive aspergillosis in a major tertiary care hospital in Bahrain[J]. J Infect Public Health,2017,10(1):49-58.
[13] 刘又宁. 肺念珠菌感染真的很少见吗[J]. 中华结核和呼吸杂志,2011,34(2):81-82.
[14] Jha BJ, Dey S, Tamang MD,et al. Characterization of Candida species isolated from cases of lower respiratory tract infection[J]. Kathmandu Univ Med J (KUMJ),2006,4(3):290-294.
[15] Osmanov A, Denning DW. Burden of serious fungal infections in Ukraine[J]. Mycoses,2015,58(Suppl 5):94-100.
[16] 刘又宁, 佘丹阳, 孙铁英,等. 中国1998年至2007年临床确诊的肺真菌病患者的多中心回顾性调查[J]. 中华结核和呼吸杂志,2011,34(2):86-90.
[17] Wang H, Wu DW, Han H, et al. Antibiotics exposure, risk factors, and outcomes with Candida albicans and non-Candida albicans candidemia. Results from a multi-center study[J]. Saudi Med J,2014,35(2):153-158.
[18] Bafadhel M, McKenna S, Agbetile J, et al. Aspergillus fumigatus during stable state and exacerbations of COPD[J]. Eur Respir J,2014,43(1):64-71.
[19] Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients[J]. Am J Health Syst Pharm,2009,66(19):1711-1717.
[20] Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient[J]. Rev Esp Quimioter,2013, 26(2):173-188.
[21] 龙军, 张耀康, 江凌晓等. 2008-2012年肺部真菌感染临床分析[J]. 中华医院感染学杂志,2014,24(13):3240-3242.
[22] Li XS, Zhu HX, Fan HX, et al. Pulmonary fungal infections after bone marrow transplantation:the value of high-resolution computed tomography in predicting their etiology[J]. Chin Med J (Engl),2011,124(20):3249-3254.
[23] Guinea J, Bouza E. Current challenges in the microbiological diagnosis of invasive aspergillosis[J]. Mycopathologia, 2014,178(5-6):403-416.
[24] 牟向东. 支气管-肺念珠菌定植和侵袭性感染的鉴别[J]. 中华结核和呼吸杂志,2008,31(6):478.
[25] León C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization[J]. Crit Care Med,2006,34(3):730-737.
[26] Cornillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients:a 6-year survey[J]. Clin Infect Dis,2006,43(5):577-584.
[27] 陈瑞英, 靳建军, 欧阳松云,等. 非中性粒细胞缺乏患者发生侵袭性曲霉病的危险因素、临床特征及预后分析[J]. 中国呼吸与危重监护杂志,2008, 7(3):169-173.
[28] 施毅. 重视非粒细胞缺乏患者侵袭性肺曲霉病的临床诊治[J]. 上海医药,2014, (9):15-19.
[29] Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients:a randomized, controlled trial[J]. Clin Infect Dis,2009, 48(8):1042-1051.
[30] Hebart H, Klingspor L, Klingebiel T, et al. A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin B in patients after allo-SCT[J]. Bone Marrow Transplant,2009,43(7):553-561.